Cancer vaccines: An update with special focus on ganglioside antigens (Review)

Oncology Reports

Volumn 9, Issue 2, 2002, Pages 267-276

  Bitton, Roberto J ^a   Guthmann, Marcelo D ^a   Gabri, Mariano R ^b   Carnero, Ariel J L ^a   Alonso, Daniel F ^b   Fainboim, Leonardo ^a   Gomez, Daniel E ^b  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Cancer vaccines; GM3; Immunotherapy

Indexed keywords

CANCER VACCINE; DRUG DERIVATIVE; GANGLIOSIDE GM3; IMMUNOGLOBULIN ALLOTYPE; N GLYCOLOYLNEURAMINYLLACTOSYLCERAMIDE; N-GLYCOLYLNEURAMINYLLACTOSYLCERAMIDE; TUMOR ANTIGEN;

ANIMAL; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; G(M3) GANGLIOSIDE; HUMANS; IMMUNOGLOBULIN GM ALLOTYPES;

EID: 0036517092     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.2.267     Document Type: Article

References (59)

1. Colley WB: A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. Postgraduate 8: 278-286, 1893.
2. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE: Immunologic and therapeutic evaluation of a syntetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998. (Pubitemid 28144091)
3. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998. (Pubitemid 28144092)
4. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M and Knuth A: Generation of cytotoxic T-cell responses with syntetic melanoma associated peptides in vivo: implications for tumor vaccines with melanoma associated antigens. Int J Cancer 66: 162-169, 1996. (Pubitemid 26248194)
5. Lowy DR and Schiller JT: Papillomaviruses: prophylactic vaccines prospects. Biochem Biophys Acta 1423: 1M-8M, 1999.
6. Lowy DR and Schiller JT: Papillomaviruses and cervical cancer: pathogenesis and vaccine development. J Natl Cancer Inst Monogr 23: 27-30, 1998.
7. Greenberg PD: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49: 281-355, 1991.
8. Schreiber H, Ward PL, Rowley DA and Stauss HJ: Unique tumor-specific antigens. Annu Rev Immunol 6: 465-483, 1988. (Pubitemid 19141592)
9. Greenberg PD, Cheever MA and Fefer A: H-2 restriction of adoptive immunotherapy of advanced tumors. J Immunol 126: 2100-2103, 1981. (Pubitemid 11072820)
10. Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986. (Pubitemid 16002234)
11. Shimizu K and Shen FW: Role of different T cell set in the rejection of syngeneic chemically induced tumors. J Immunol 122: 1162-1165, 1979. (Pubitemid 9150607)
12. + T cells in antitumor immunity. Trends Immunol 22: 269-276, 2001.
13. Van den Eynde B and van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol 9: 684-693, 1997.
14. Livingston PO, Ragupathi G and Musselli C: Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. J Clin Immunol 20: 85-93, 2000. (Pubitemid 30314312)
15. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P and Amigorena S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1: 362-368, 1999. (Pubitemid 129493579)
16. Wells AD and Malkovsky M: Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol Today 21: 129-132, 2000. (Pubitemid 30122702)
17. Gumperz JE and Brenner MB: CD1-specific T cells in microbial immunity. Curr Opin Immunol 13: 471-478, 2001. (Pubitemid 32728481)
18. Shamshiev A, Donda A, Carena I, Mori L, Kappos L and De Libero G: Self glycolipids as T-cell autoantigens. Eur J Immunol 29: 1667-1675, 1999. (Pubitemid 29224472)
19. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C and Livingston PO: Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85: 659-666, 2000. (Pubitemid 30080479)
20. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ and Livingston PO: Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 6: 874-879, 2000. (Pubitemid 30159343)
21. Alonso DF, Gabri MR, Guthmann MD, Fainboim L and Gomez DE: A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Int J Oncol 15: 59-66, 1999.
22. Carr A, Mazorra Z, Alonso DF, Mesa C, Valiente O, Gomez DE, Perez R and Fernandez LE: A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res 11: 219-227, 2001. (Pubitemid 32578808)
23. Johnsen AK, Templeton DJ, Sy M and Harding CV: Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 163: 4224-4231, 1999. (Pubitemid 29474486)
24. Franksson L, George E, Powis S, Butcher G, Howard J and Karre K: Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene. J Exp Med 177: 201-205, 1993. (Pubitemid 23008101)
25. Fedarko NS, Fohr B, Robey PG, Young MF and Fisher LW: Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 275: 16666-16672, 2000. (Pubitemid 30398895)
26. Finke J, Ferrone S, Frey A, Mufson A and Ochoa A: Where are all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 20: 158-160, 1999. (Pubitemid 29172275)
27. Heitger A and Ladisch S: Gangliosides block antigen presentation by human monocytes. Biochim Biophys Acta 1303: 161-168, 1996. (Pubitemid 26325547)
28. Garofalo T, Sorice M, Misasi R, Cinque B, Giammatteo M, Pontieri GM, Cifone MG and Pavan A: A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3. Involvement of serine phosphorylation and protein kinase c delta translocation. J Biol Chem 273: 35153-35160, 1998. (Pubitemid 29028219)
29. McKallip R, Li R and Ladisch S: Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 163: 3718-3726, 1999. (Pubitemid 29450894)
30. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N and Schuler G: High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184: 741-746, 1996. (Pubitemid 26324128)
31. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L and Mantovani A: IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 28: 359-369, 1998. (Pubitemid 28048306)
32. Kanda N: Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem Biophys Res Commun 256: 41-44, 1999.
33. Halak BK, Maguire HC and Lattime EC: Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 59: 911-917, 1999. (Pubitemid 29086748)
34. Reichert TE, Rabinowich H, Johnson JT and Whiteside TL: Mechanisms responsible for signaling and functional defects. J Immunother 21: 295-306, 1998. (Pubitemid 28328409)
35. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J and Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366, 1996. (Pubitemid 26391458)
36. Cho D, Song H, Kim YM, Houh D, Hur DY, Park H, Yoon D, Pyun KH, Lee WJ, Kurimoto M, Kim YB, Kim YS and Choi I: Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 60: 2703-2709, 2000. (Pubitemid 30318247)
37. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T and Koji T: Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 6: 3560-3564, 2000.
38. Ockert D, Schmitz M, Hampl M and Rieber EP: Advances in cancer immunotherapy. Immunol Today 20: 63-65, 1999. (Pubitemid 29136629)
39. Berd D, Maguire HC Jr, McCue P and Mastrangelo MJ: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 8: 1858-1867, 1990. (Pubitemid 20382349)
40. Elliott GT, McLeod RA, Perez J and von Eschen KB: Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 9: 264-272, 1993. (Pubitemid 23154466)
41. Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T and Mastrangelo MJ: Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15: 2359-2370, 1997. (Pubitemid 27251139)
42. Liu MA: Vaccine developments. Nat Med 4: 515-519, 1998. (Pubitemid 28228084)
43. Polo JM and Dubensky TWJ: DNA vaccines with a kick. Nat Biotechnol 16: 517-518, 1998. (Pubitemid 128723273)
44. Herlyn D and Birebent B: Advances in cancer vaccine development. Ann Med 31: 66-78, 1999. (Pubitemid 29134487)
45. Naftzger C, Takechi Y, Kohda H, et al: Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 93: 14809-14814, 1996. (Pubitemid 26419051)
46. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B Engleman EG and Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58, 1996. (Pubitemid 26028073)
47. Jerne NK: Towards a network theory of the immune system. Ann Immunol (Paris) 125C: 373-389, 1974.
48. Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA and Bhattacharya-Chatterjee M: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18: 376-384, 2000. (Pubitemid 30056428)
49. Shepherd FA: Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer. Semin Oncol 28: 30-37, 2001.
50. Moreno E, Lanne B, Vazquez AM, Kawashima I, Tai T, Fernandez LE, Karlsson KA, Angstrom J and Perez R: Delineation of the epitope recognized by an antibody specific for N-Glycolylneuraminic acid-containing gangliosides. Glycobiology 8: 695-705, 1998. (Pubitemid 28331445)
51. Vazquez AM, Gabri M, Hernandez AM, Alonso DF, Beausoleil I, Gomez DE and Perez R: Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-Glycolyl-containing gangliosides. Oncol Rep 7: 751-756, 2000.
52. Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S and Ferrone S: Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1: 705-713, 1995.
53. Yao TJ, Meyers M, Livingston PO, Houghton AN and Chapman PB: Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 5: 77-81, 1999. (Pubitemid 29045180)
54. Park SH and Bendelac A. CD1-restricted T-cell responses and microbial infection. Nature 406: 788-792, 2000.
55. Deng W, Li R and Ladish S: Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 92: 912-917, 2000. (Pubitemid 30429191)
56. Hamilton WB, Helling F, Lloyd KO and Livingston PO: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 53: 566-573, 1993. (Pubitemid 23069265)
57. Kiura K, Watarai S, Ueoka H, Tabata M, Gemba K, Aoe K, Yamane H, Yasuda T and Harada M: An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line. Anticancer Res 18: 2957-2960, 1998. (Pubitemid 28388797)
58. Kirkwood J, Ibrahim J, Sosman J, Sondak V, Agarwala S, Emstoff M and Rao U: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with de GMK-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol 19: 2370-2380, 2001. (Pubitemid 32391207)
59. Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, Sierra G and Fernandez LE: Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 18: 190-197, 1999. (Pubitemid 29432152)